Reagents News and Research

RSS

ParoChip can allow dentists to quickly detect and analyze periodontitis pathogens

Bleeding gums during tooth brushing or when biting into an apple could be an indication of periodontitis, an inflammatory disease of the tissues that surround and support the teeth. Bacterial plaque attacks the bone, meaning teeth can loosen over time and in the worst case even fall out, as they are left without a solid foundation to hold them in place.

4 Jan 2013

Viewpoints: Playing chicken on entitlements; 'Getting serious' about mental illness; Hospital labs devastated by Sandy

This is no time for a Grand Bargain, because the Republican Party, as now constituted, is just not an entity with which the president can make a serious deal. If we're going to get a grip on our nation's problems - of which the budget deficit is a minor part - the power of the G.O.P.'s extremists, and their willingness to hold the economy hostage if they don't get their way, needs to be broken. And somehow I don't think that's going to happen in the next few days (Paul Krugman, 12/20).

21 Dec 2012

GeneTex to introduce new Histone H3 antibody

GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.

11 Dec 2012

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

Beckman Coulter Life Sciences is expanding their flow cytometry portfolio with the addition of 14 new human monoclonal antibodies from Trillium Diagnostics LLC.

From Beckman Coulter Life Sciences - Flow Cytometry 30 Nov 2012

China's SFDA approves QIAGEN careHPV Test and instrument platform

QIAGEN N.V. today announced that China's State Food and Drug Administration (SFDA) has approved QIAGEN's careHPV Test and instrument platform.

From QIAGEN Manchester Limited 29 Nov 2012

United States Pharmacopeial Convention to host Fifth Bioassay Workshop in Rockville

As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products.

17 Nov 2012

New England Biolabs launches new NEBNext Ultra kits at ASHG annual meeting

New England Biolabs, Inc. launched their new NEBNext "Ultra" kits at the recent American Society for Human Genetics annual meeting.

From New England Biolabs 17 Nov 2012

Texas Biomed develops rapid, less expensive route to screen suitable tests for bioterror threats

Texas Biomedical Research Institute scientists in San Antonio have developed a faster, less expensive route to screen suitable tests for bioterror threats and accelerate the application of countermeasures.

7 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Affymetrix reports net loss of $17.9 million for third quarter 2012

Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.

5 Nov 2012

CSHL scientists discover new way to specifically target and kill cancer cells

Cancer cells grow fast. That's an essential characteristic of what makes them cancer cells. They've crashed through all the cell-cycle checkpoints and are continuously growing and dividing, far outstripping our normal cells. To do this they need to speed up their metabolism.

1 Nov 2012

CDC report outlines international influenza activities

The Centers for Disease Control and Prevention (CDC) on Monday released a 268-page annual report that "profiles a wide range of CDC influenza-related projects around the world, from flu surveillance in Indonesia to vaccine effectiveness studies in El Salvador and epidemiology training in Ghana," CIDRAP News reports.

1 Nov 2012

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

To support their research for a vaccine against the HI-Virus, Prof. Dr. Klaus Überla of the Faculty for Medicine at the Ruhr-Universität Bochum and his research team will receive $2.3 million in funding within the next three years from the Bill & Melinda Gates Foundation. The scientists are part of the Collaboration for AIDS Vaccine Discovery (CAVD), which seeks to speed up the development of an HIV-vaccine through a rigorous exchange of information, methods and reagents.

29 Oct 2012

New method of testing for West Nile virus

While the United States has largely been spared the scourge of mosquito-borne diseases endemic to the developing world-including yellow fever, malaria and dengue fever-mosquito-related illnesses in the US are on the rise. One pathogen of increasing concern in the U.S. is an arbovirus known as West Nile.

24 Oct 2012

Potential biomarker diagnostic test for pre-eclampsia

Collaborators at Cottage Health System and University of California, Santa Barbara (UCSB) have identified biomarkers that may yield a revolutionary diagnostic test for pre-eclampsia, a complex and potentially life-threatening hypertensive condition affecting 5% of pregnancies worldwide.

22 Oct 2012

FDA licenses Quotient’s ALBAsera products

Quotient Biodiagnostics, Inc., a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that its range of ALBAsera Rare Antisera products have been licensed for sale by the U.S. Food and Drug Administration (FDA).

5 Oct 2012

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012